Synovial Sarcoma Registry / Biospecimen Repository
Synovial Sarcoma Registry and Biospecimen Repository
1 other identifier
observational
1,000
1 country
1
Brief Summary
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2023
CompletedStudy Start
First participant enrolled
June 12, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2033
June 9, 2026
June 1, 2026
5 years
June 1, 2023
June 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of patients with synovial sarcoma
Number of patients with synovial sarcoma
Up to 10 years
Eligibility Criteria
Males and females of any age with a reported diagnoses of synovial sarcoma.
You may qualify if:
- Males or females of any age
- Reported diagnosis of synovial sarcoma
- Informed consent from subject (aged ≥18 years) or parent/guardian
You may not qualify if:
- Individuals with sarcomas that do not fit the definition of those considered for this registry
- Individuals who are unwilling to participate
- Individuals who are unwilling or unable to provide written consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Related Links
Biospecimen
Samples may include tumor tissue and its excipients (DNA, RNA, protein), blood, saliva, and/or buccal swabs.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Theodore Laetsch, MD
Children's Hospital of Philadelphia
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 1, 2023
First Posted
June 18, 2023
Study Start
June 12, 2023
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
June 1, 2033
Last Updated
June 9, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Upon request, data can be made available after review by study team.
- Access Criteria
- The study team will review requests on an individual basis.
De-identified data and specimens may be provided to other investigators for additional research use. Identifiable data will only be available to the study team.